Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

DISEASE CHARACTERISTICS:

Diagnosis of metastatic cancer

Tumor overexpresses p53 as assessed by immunohistochemistry (i.e., ≥ 5% tumor cells stain positive for p53)

Biopsy must be available to evaluate p53 expression
Human leukocyte antigens 0201 (HLA-A*0201) positive

Progressive or recurrent disease after prior standard therapy for metastatic disease

Patients with melanoma or renal cell cancer must have previously received aldesleukin
Patients with other histologies, not including hematologic malignancies, must have previously received first-line and second-line or higher systemic standard therapy (or effective salvage chemotherapy regimens)

PATIENT CHARACTERISTICS:

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy > 3 months
Absolute neutrophil count > 1,000/mm^3
White blood cell (WBC) > 3,000/mm^3
Platelet count > 100,000/mm^3
Hemoglobin > 8.0 g/dL
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal
Serum creatinine ≤ 1.6 mg/dL
Total bilirubin ≤ 2.0 mg/dL (< 3.0 mg/dL in patients with Gilbert's syndrome)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 4 months after completion of study treatment
Patients who have previously received ipilimumab or ticilimumab must have a normal colonoscopy with normal colonic biopsies
Human immunodeficiency virus (HIV) antibody negative
Hepatitis B antigen and hepatitis C antibody negative (unless antigen negative)
No primary immunodeficiency (e.g., severe combined immunodeficiency disease)
No active systemic infections
No history of severe immediate hypersensitivity reaction to any of the agents used in this study
No coagulation disorders
No myocardial infarction or cardiac arrhythmias
No history of coronary revascularization
No obstructive or restrictive pulmonary disease
No contraindications for high-dose aldesleukin administration

Left ventricular ejection fraction (LVEF) ≥ 45% in patients meeting any of the following criteria:

History of ischemic heart disease,
chest pain,
or clinically significant atrial and/or ventricular arrhythmias including, but not limited to, atrial fibrillation,
ventricular tachycardia,
or second- or third-degree heart block
At least 60 years of age

Forced expiratory volume 1 (FEV_1) > 60% predicted in patients meeting any of the following criteria:

Prolonged history of cigarette smoking (> 20 pack/year within the past 2 years)
Symptoms of respiratory dysfunction

No other major medical illness of the cardiovascular,

respiratory,
or immune system

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior therapy
More than 4 weeks since prior and no concurrent systemic steroid therapy
More than 4 weeks since other prior systemic therapy
More than 6 weeks since prior ipilimumab